1Torre LA, Trabert B, DeSantis CE. (2018) Ovarian cancer statistics. CA Cancer J Clin. 4:284-296.

2Jung KW, Won YJ, Kong HJ, Lee ES. (2018) Community of Population-Based Regional Cancer R. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015. Cancer Res Treat. 2:303-316.

3Tseng JJ, Chen YH, Chiang HY, Lin CH. (2017) Increased risk of breast cancer in women with uterine myoma: a nationwide, population-based, case-control study. J Gynecol Oncol. 3: e35.

4Hanson B, Johnstone E, Dorais J, Silver B, Peterson CM, Hotaling J. (2017) Female infertility, infertility-associated diagnoses, and comorbidities: a review. J Assist Reprod Genet. 2:167-177.

5Fleming CA, Heneghan HM, O'Brien D, McCartan DP, McDermott EW, Prichard RS. (2018) Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy. Br J Surg.

6Rachner TD, Coleman R, Hadji P, Hofbauer LC. (2018) Bone health during endocrine therapy for cancer. Lancet Diabetes Endocrinol.

7Leon-Ferre RA, Majithia N, Loprinzi CL. (2017) Management of hot flashes in women with breast cancer receiving ovarian function suppression. Cancer Treat Rev. 52:82-90.

8Reinert T, Nogueira-Rodrigues A, Kestelman FP, Ashton-Prolla P, Graudenz MS, Bines J. (2018) The Challenge of Evaluating Adnexal Masses in Patients with Breast Cancer. Clin Breast Cancer. 4: e587-e594.

9Pal T, Vadaparampil ST. (2012) Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting. Cancer Control. 4:255-266.

10Le D, Gelmon KA. (2018) Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer. Expert Rev Clin Pharmacol. 9:833-839.

11Kushner CJ, Hwang WT, Wang S, Solin LJ, Vapiwala N. (2018) Long-term risk of second malignancies in women after breast conservation therapy for ductal carcinoma in situ or early-stage breast cancer. Breast Cancer Res Treat. 1:45-53.

12Roukos DH, Briasoulis E. (2007) Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome. Nat Clin Pract Oncol. 10:578-590.

13Schlich-Bakker KJ, ten Kroode HF, Ausems MG. (2006) A literature review of the psychological impact of genetic testing on breast cancer patients. Patient Educ Couns. 1:13-20.

14Tuffaha HW, Mitchell A, Ward RL, et al. (2018) Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers. Genet Med.

15Sie AS, van Zelst-Stams WA, Spruijt L. (2014) More breast cancer patients prefer BRCA-mutation testing without prior face-to-face genetic counseling. Fam Cancer. 2:143-151.

16Wevers MR, Hahn DE, Verhoef S. (2012) Breast cancer genetic counseling after diagnosis but before treatment: a pilot study on treatment consequences and psychological impact. Patient Educ Couns. 1:89-95.

17Fournier DM, Bazzell AF, Dains JE. (2018) Comparing Outcomes of Genetic Counseling Options in Breast and Ovarian Cancer: An Integrative Review. Oncol Nurs Forum. 1:96-105.

18Hoskins PJ, Gotlieb WH. (2017) Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature. CA Cancer J Clin. 6:493-506.

19Graffeo R, Livraghi L, Pagani O, Goldhirsch A, Partridge AH, Garber JE. (2016) Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care. Breast Cancer Res Treat. 3:393-410.

20Beitsch PD, Whitworth PW. (2014) Can breast surgeons provide breast cancer genetic testing? An American Society of Breast Surgeons survey. Ann Surg Oncol. 13:4104-4108.

21Sharma P, Klemp JR, Kimler BF. (2014) Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat. 3:707-714.

22Biron-Shental T, Drucker L, Altaras M, Bernheim J, Fishman A. (2006) High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma. Eur J Surg Oncol. 10:1097-1100.

23Santen RJ, Stuenkel CA, Davis SR, Pinkerton JV, Gompel A, Lumsden MA. (2017) Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors. J Clin Endocrinol Metab. 10:3647-3661.

24Tao WW, Tao XM, Song CL. (2017) Effects of nonpharmacological supportive care for hot flushes in breast cancer: meta-analysis. Support Care Cancer. 7:2335-2347.

25Reid DM, Doughty J, Eastell R. (2008) Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev. 1: S3-18.

26Sun Y, Kang E, Baek H. (2015) Participation of Korean families at high risk for hereditary breast and ovarian cancer in BRCA1/2 genetic testing. Jpn J Clin Oncol. 6:527-532.